Zobrazeno 1 - 10
of 10
pro vyhledávání: '"W. F. Kline"'
Autor:
Peggy H. Wong, Catherine Z. Matthews, Josee Cote, Marshall Sack, Nancy G. B. Agrawal, Eric Woolf, Arturo G. Porras, Richard Robson, Leslie A. Geer, Suzanne K. Swan, W. F. Kline, Ralph S. Mazenko, Kevin J. Petty, Harry Alcorn, Keith Gottesdiener, Meehung Cho, Thomas Marbury, Jack W. Moncrief, Jules I. Schwartz
Publikováno v:
The Journal of Clinical Pharmacology. 44:48-58
The effect of renal insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, was examined in 23 patients with varying degrees of renal impairment (12 moderate [creatinine clearance between 30 and 50 mL/min/1.73
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 22:2125-2137
A sensitive and selective method for the determination of 1-(((7,7-dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl) butyramido)-bicyclo[2.2.1]-heptan-1(S)-yl) methyl) sulfonyl) - 4 - (2 - methyl-phenyl)-piperazine (L-368,899) in human plasma is described
Autor:
J. Orgee, S. Khan, Samuel D Vasikaran, G. Coombes, Monique N.C. Beneton, W. F. Kline, Arturo G. Porras, David G. Sciberras, Barry J. Gertz, Eugene V. McCloskey, S. Rogers, Sherry D. Holland, Bogdan K. Matuszewski, John A. Kanis
Publikováno v:
Journal of Bone and Mineral Research. 12:1700-1707
Postmenopausal women with established vertebral osteoporosis were studied for 2 years to determine the terminal elimination half-life and the duration of response to treatment with intravenous alendronate (30 mg) given over 4 days. The urinary excret
Autor:
W. F. Kline, Bogdan K. Matuszewski, Sherry D. Holland, Amanda Freeman, Kenneth C. Lasseter, Barry J. Gertz, John C. Mucklow, Arturo G. Porras, Hui Quan
Publikováno v:
Clinical Pharmacology & Therapeutics. 58:288-298
Clinical studies were performed to examine the oral bioavailability of alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate monosodium). All studies, with the exception of one performed in men, involved postmenopausal women. Short-term (24 to
Publikováno v:
Osteoporosis International. 3:13-16
Clinical studies have been performed to investigate the pharmacokinetics and pharmacodynamics of alendronate, an inhibitor of bone resorption for the treatment of osteoporosis. Alendronate is one of the most potent bisphosphonates currently undergoin
Publikováno v:
Biomedical chromatography : BMC. 19(7)
Achiral and chiral liquid chromatographic methods utilizing mass spectrometric detection were developed to investigate the possibility of inversion of configuration at any or all of the chiral centers of the neurokinin-1 (NK-1) receptor antagonist, a
Autor:
Barry J. Gertz, Kanying E. Zhang, W. F. Kline, Kamlesh P. Vyas, Hui Quan, Simon Van Belle, Marina DeSmet, Jacques De Greve, Arturo G. Porras, Veronique Cocquyt, Sherry D. Holland
Publikováno v:
Journal of clinical pharmacology. 39(4)
Alendronate is a potent bisphosphonate that has been studied for the treatment of osteoporosis and Paget's disease of the bone. To examine the pharmacokinetics of this drug, several groups of postmenopausal women were dosed intravenously in several s
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 276(1)
Alendronate (4-amino-1-hydroxybutylidene bisphosphonate, ALN) is an aminobisphosphonate that is being developed for the treatment of diseases characterized by increased bone resorption. The purpose of this study was to assess the long-term safety of
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 9(6)
Publikováno v:
Journal of Liquid Chromatography. 8:223-237
A sequential liquid chromatographic (LC) procedure for the determination of polycyclic aromatic hydrocarbons (PAH) in a petroleum crude oil and other complex mixtures is described. The procedure includes normal-phase LC on an aminosilane column to is